Aldeyra Therapeutics (ALDX) Non-Current Debt (2013 - 2025)

Aldeyra Therapeutics' Non-Current Debt history runs 13 years deep, the most recent figure standing at $15.0 million for Q4 2025.

• Quarterly Non-Current Debt changed 0.0% year-over-year to $15.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.0 million (changed 0.0% YoY) and the FY2025 annual result came in at $15.0 million, changed 0.0% from the prior year.
• Non-Current Debt was $15.0 million for Q4 2025 at Aldeyra Therapeutics, roughly flat from $15.0 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $15.4 million in Q3 2021 and bottomed at $2.7 million in Q3 2023.
• A 5-year average of $14.0 million and a median of $15.0 million in 2021 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2023 — Non-Current Debt sank 82.29% — and 2024, when it surged 464.51%.
• Aldeyra Therapeutics' Non-Current Debt stood at $15.0 million in 2021, then slipped by 0.51% to $14.9 million in 2022, then tumbled by 82.19% to $2.7 million in 2023, then jumped by 464.51% to $15.0 million in 2024, then changed by 0.0% to $15.0 million in 2025.
• Business Quant data shows ALDX's Non-Current Debt at $15.0 million in Q4 2025, $15.0 million in Q3 2025, and $15.1 million in Q1 2025.